107 terminated. 107 Phase 1, 34 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 107 | Terminated 107 |
| Phase 2 | 34 | Terminated 34 |
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia | Phase 1 | Terminated | Antonio M Jimenez Jimenez | 2 | 2024-12-04 | 2026-07-13 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome BMS-986497, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | Bristol-Myers Squibb | 34 | 2024-05-29 | 2026-10-01 |
| Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2023-11-20 | 2026-06-25 |
| Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ABBV-787 - Acute Myeloid Leukemia | Phase 1 | Terminated | AbbVie | 36 | 2023-11-13 | 2025-03-06 |
| A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine Cladribine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2023-10-09 | 2026-07-30 |
| Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Biospecimen Collection, Tomivosertib - Acute Myeloid Leukemia | Phase 1 | Terminated | Northwestern University | 8 | 2023-09-29 | 2026-06-11 |
| Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome SGR-2921 - Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes | Phase 1 | Terminated | Schrödinger, Inc. | 66 | 2023-09-27 | 2025-09-22 |
| First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia AFM28 - Acute Myeloid Leukemia | Phase 1 | Terminated | Affimed GmbH | 30 | 2023-03-21 | 2025-07-23 |
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant Siremadlin - Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2023-02-23 | 2025-05-16 |
| CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia LCAR-AMDR Cells Product - Acute Myeloid Leukemia | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 4 | 2022-12-12 | 2026-02-11 |
| Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Uproleselan, Fludarabine, Clofarabine - Acute Myeloid Leukemia, Pediatric Cancer | Phase 1 | Terminated | Malika Kapadia | 1 | 2022-10-06 | 2024-08-19 |
| A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics AUR103 - Solid Tumor, Adult, Acute Myeloid Leukemia | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 27 | 2022-09-16 | 2026-04-17 |
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML SL-172154, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Shattuck Labs, Inc. | 106 | 2022-03-17 | 2026-03-18 |
| Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) MGTA-117 - Acute Myeloid Leukemia, Myelodysplasia | Phase 1 | Terminated | Magenta Therapeutics, Inc. | 22 | 2022-02-14 | 2023-02-09 |
| XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia XmAb18968 - Dose level -1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 1 - Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Ehab L Atallah | 22 | 2022-02-02 | 2025-05-08 |
| A Study of BTX-1188 in Subjects With Advanced Malignancies BTX-1188 - Advanced Solid Tumor, Non Hodgkin Lymphoma | Phase 1 | Terminated | Biotheryx, Inc. | 8 | 2022-01-24 | 2026-10-15 |
Showing 20 of 107. Sign in to see all of them.
Leukemia, Myeloid, Acute (107) · Myelodysplastic Syndromes (27) · Recurrence (15) · Leukemia (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Lymphoma, Non-Hodgkin (9) · Multiple Myeloma (8) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Neoplasms (7) · Hematologic Neoplasms (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Myelomonocytic, Chronic (6) · Lymphoma, Large B-Cell, Diffuse (3) · Myeloproliferative Disorders (3) · Primary Myelofibrosis (3)
Hematologic Diseases (107) · Hemic and Lymphatic Diseases (107) · Neoplasms by Histologic Type (107) · Leukemia, Myeloid (106) · Neoplasms (100) · Leukemia (95) · Bone Marrow Diseases (31) · Pathologic Processes (29) · Pathological Conditions, Signs and Symptoms (29) · Disease Attributes (28) · Immune System Diseases (27) · Immunoproliferative Disorders (27) · Lymphoproliferative Disorders (27) · Lymphatic Diseases (25) · Leukemia, Lymphoid (18)
Azacitidine (19) · Cytarabine (16) · venetoclax (14) · fludarabine (9) · Cyclophosphamide (7) · fludarabine phosphate (6) · Daunorubicin (5) · Decitabine (4) · Gemtuzumab (4) · Busulfan (3) · Etoposide (3) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (2) · Clofarabine (2) · Dexamethasone (2) · Filgrastim (2)
M.D. Anderson Cancer Center (7) · Novartis Pharmaceuticals (4) · Astex Pharmaceuticals, Inc. (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University Health Network, Toronto (3) · AbbVie (2) · Astellas Pharma Global Development, Inc. (2) · Gilead Sciences (2) · Hoffmann-La Roche (2) · National Cancer Institute (NCI) (2) · Pfizer (2) · Seagen Inc. (2) · ADC Therapeutics S.A. (1) · AGC Biologics S.p.A. (1) · ALX Oncology Inc. (1)
United States (85) · Canada (11) · France (11) · Spain (11) · Italy (8) · Germany (7) · Australia (6) · United Kingdom (6) · Netherlands (5) · China (4) · Japan (4) · Czechia (3) · Greece (3) · Poland (3) · South Korea (3)
Aaron Goldberg, MD (1) · Ai-Li He, MD, PhD (1) · Akhil Kumar, MD (1) · Alexander Ambinder, MD (1) · Allen R. Chen, MD,PhD. MHS (1) · Ann Dahlberg (1) · Antonio M Jimenez Jimenez, MD (1) · Aude Chapuis (1)
PMID 23400739, PMID 24200998, PMID 24355079, PMID 29142066, PMID 29296751, PMID 32476546, PMID 32521310, PMID 33554732, PMID 33787078, PMID 36841672, PMID 36865133, PMID 37386016, PMID 38841781, PMID 38871487, PMID 40198769, PMID 40209615, PMID 40327322, PMID 41075807, PMID 42736326
2018 (3), 2023 (3), P30CA015704 (2), 2008 (1), 2015 (1), 2016 (1), 2017 (1), N01CM00100 (1), P01CA018029 (1), P30CA016672 (1), P30CA060553 (1), P30CA093373 (1), UM1CA186644 (1), UM1CA186712 (1), UM1CA186716 (1)